



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/982,093

10/19/2001

S. Rao Cherukuri

69710.000005

6757

21967

7590

08/19/2008

HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109

EXAMINER

FUBARA, BLESSING M

ART UNIT

PAPER NUMBER

1618

MAIL DATE

DELIVERY MODE

08/19/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/982,093	Applicant(s) CHERUKURI, S. RAO	
	Examiner BLESSING M. FUBARA	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 May 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 25 and 27-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25 and 27-35 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The examiner acknowledges receipt of request for extension of time, power of attorney, exhibit A, amendment, and remarks, all filed 5/01/08.

Claims 3-24 and 26 are canceled. New claims 28-32 and 34-36 are added. Claims 25 and 27-35 are pending after renumbering the claims according to 37 CFR 1.126.

Claim Numbering:

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Applicant is requested to number claims consecutively numbered as required by 37 CFR 1.126 because there is no claim 33. Thus, applicant must renumber claims 34-36 as 33-35 in accordance with 37 CFR 1.126. It is suggested that the claims be consecutively numbered in all future correspondences.

Response to Arguments

Previous rejections that are not reiterated herein are withdrawn. Applicant's arguments with respect to Carnmalm, Batista, Wong and Cupps are moot because the amendment necessitated the new grounds of rejections described below.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1618

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 25, 27-29, 31-35 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is new matter rejection.

Claim 25 and new claim 35 give the diameter and length of the caplet as ranging from about 1 millimeter to about 3 millimeter. The specification at the abstract and at paragraphs [0019], [0023] and [0074] of the published application and original claim 1 disclose and recite that the diameter of the caplet is from about 1 millimeter to about 7 millimeter. Paragraphs [0098], [0101], [0104] and [0107] of the published application disclose caplets having specific diameter of 3 millimeter and 1.3 millimeter. The specification as originally filed does not envision diameters in the range of about 1 millimeter to about 3 millimeters. This is new matter.

The above rejection may be overcome by removing the new matter from the claims.

Response to Arguments

3. Applicant's arguments filed 05/01/08 have been fully considered but they are not persuasive.

4. Applicant argues that the claimed diameter and length of the caplet in the range of from 1 millimeter to about 3 millimeter does not have to be disclosed *ipsis verbis* because the disclosed range of 1 millimeter to about 7 millimeter and a specific disclosure for a diameter and length of 3 millimeter supports the claimed range. The examiner disagrees. A range of 1 millimeter to about 3 millimeter is what it is since the upper limit of about 3 is much less than

Art Unit: 1618

4.5, say. Contrary to applicant's assertion, the Office action specifically stated that the claimed range is not envisioned by the originally filed application. While the 3 millimeter specie may be part of the disclosed genus of 1-7 and the claimed genus of 1-3, the genus range of 1-7 does not provide support for the genus range of 1-3.

5. Claims 25, 27-30 and 31-34 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is new matter rejection.

6. Amended claim 25 defines the binder as polyvinylpyrrolidone polymer. Applicant has said that support for the limitation of polyvinylpyrrolidone (PVP) is found in Examples 1 and 2. But Examples 1 and 2 use specific forms of the PVP, povidone K30 (Example 1) and plasdone k-29/32 (Example 2). The specification as originally filed does not envision generic polyvinylpyrrolidone.

The above rejection may be overcome by removing the new matter from the claims.

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1618

8. Claims 25, 27-32, 34 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jerussi et al. (US 6,197,828).

9. Jerussi describes pharmaceutical dosages in the form of tablets, caplets, troches, lozenges (column 15, line 34; column 16, line 14); the dosage form comprises pharmaceutical carrier/binder/filler in pharmaceutically compatible and pharmaceutically acceptable amounts and active ingredient (column 15, lines 38-43; column 17, lines 14-22); the binder is “corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose,... microcrystalline cellulose, and mixtures thereof,” (column 17, line 65 to column 18, line 7); disintegrants are “agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algin, other celluloses, gums or mixtures thereof” (column 18, lines 44-50); lubricants are “calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof” (column 18, lines 51-59); the active ingredient is pharmaceutically venlafaxine or venlafaxine derivative (column 2, lines 43-47) or pharmaceutically acceptable salt (column 3, line 14), and included in the pharmaceutical salt is the hydrochloride salt (column 4, line 43). The hydrochloride salt of venlafaxine meets the venlafaxine HCl of claim 25; the lubricating agents

Art Unit: 1618

meet the claim 25 c) and 35 b); the calcium carbonate meets claim 25 b) and claim 34 and 36 a); the polyvinylpyrrolidone meets the binder of claim 25 d; the microcrystalline cellulose meets claim 29. For claims 31 and 32, the lubricating agent when applied would inherent form a film and because the lubricating agents of the prior art are the same as those recited in claim 25 c), the lubricating agents of the prior art are hydrophobic. While column 19, lines 1-7 disclosed mg amount of the active agent, Jerussi broadly teaches the above described dosage form; and for claims 27 and 28, the artisan is capable of designing caplet or tablet dosage form that comprises desired amounts of active agents and carrier/filler/binder for delivery and treatment of the various disorders disclosed (see column 4, line 50 to column 5, line 60).

The difference between the claims and Jerussi is that Jerussi is silent on the dimensions of the caplet. However, it would have been obvious to prepare the caplet having desired dimensions of length and diameter because the technique of tableting using commercially available tablet press is well recognized as part of the ordinary capabilities of the skilled artisan so that it would have been obvious to prepare caplets having desired dimensions of length and diameter. In the absence of factual evidence, caplet having the recited dimensions of length and diameter is not inventive over the caplet of the prior art that is silent on the dimensions of the caplet keeping in mind that caplets inherently have length and diameter.

Response to Arguments

10. Applicant's arguments filed 05/01/08 have been fully considered but they are not persuasive.

11. Applicant's arguments regarding January 14, 2005 presentation is addressed as it applies to the present rejections.

Art Unit: 1618

- a) Applicant says that on January 14, 2005, applicant submitted factual evidence demonstrating the unique properties of the claimed invention. But examination of the file does not show that any declaration was filed on 1/14/05.
- b). Applicant says that the factual evidence presented on 1/14/05 is commensurate with the scope of claim 25 and as such claim 25 is inventive over the prior art. The examiner disagrees. The dimensions of the caplet recited in the generic claim is a range of 1-3 mm. On 1/14/05 applicant described of compositions (12 and 13 of the remarks filed 1/14/05) and indicated that a dissolution profile in 0.1N HCl of 11 mm tablet and 3 mm caplet was presented a an attached chart. But Jerussi teaches caplet formulation and it is unclear how comparison of dissolution profile between 11 mm tablet, 3 mm caplet and dimensionless capsule is evidence that a caplet having diameter and length in the range of 1-3 mm (7 mm) is unexpected and superior to another caplet with a realization that caplets by design have dimension, even if the prior art is silent on the dimensions; and that the artisan has the technical knowledge to determine those dimensions.
- c) In the current remarks at page 7, the applicant prepares three products, i) capsule, ii) 11 mm tablet and iii) 3 mm caplet; tests the dissolution profile in 0.1 N HCl and shows dissolution profile of the three in Exhibit A. The examiner disagrees that the dissolution profile presented in Exhibit A and the products tested as described on page 7 of the present remarks filed 5/1/08 makes the instant composition patentable over the composition of the prior art. Firstly, the composition on page 7 of the present remarks filed 5/1/08 is not a representation of the claimed product/composition in claim 25 since no amounts of the venlafaxine, lubricating agent and binder is recited. Secondly, Jerussi contemplates and teaches caplet dosage form. Thirdly, the dissolution profile compares different sizes of tablets and caplets instead of comparing caplets of different dimensions. Fourthly, the generic claim recites the dimensions in a range of 1-3, and

Art Unit: 1618

the data does not show what happens at dimensions outside the recited range using caplets of varying dimensions.

d) Therefore, the data presented does not provide unexpected results over the caplet dosage form of Jerussi that contains venlafaxine, lubricant, binders and fillers.

12. Claims 25 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jerussi et al. (US 6,197,828) in view of Appel et al. (US 2002/0015731) or Chungi et al. (US 6,306,436).

13. Jerussi has been described above to render claim 25 obvious by teaching venlafaxine containing dosage in the form of caplet and comprising venlafaxine hydrochloride salt, binders, lubricant, disintegrants and fillers. While the composition of Jerussi contains polyvinylpyrrolidone, the composition of Jerussi does not contain polyvinyl acetate.

But formulations containing venlafaxine are known to contain polyvinyl acetate. For example, Appel discloses compositions containing venlafaxine and polyvinyl acetate (paragraphs [0036] and [0038]). Chungi also teaches compositions that contains venlafaxine and mixture of polyvinyl acetate and polyvinylpyrrolidone and in this case, the mixed carrier comprising mixture of polyvinyl acetate and polyvinylpyrrolidone is reported to stabilize the composition (column 5, lines 58-60; column 7, line 42, claims 14-16). Thus, Appel and Chungi are relied upon for teaching that polyvinyl acetate can be included with Venlafaxine. Therefore, taking the teachings of the prior art, one having ordinary skill in the art at the time the invention was made would have reasonable expectation of success that including polyvinyl acetate in the composition of Jerussi would lead to the desired dosage form and also assist in stabilizing the composition.

No claim is allowed.

Art Unit: 1618

14. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M. FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

/Blessing M. Fubara/
Examiner, Art Unit 1618